[1]
|
中华医学会呼吸病学分会肺栓塞与肺血管病血组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版) [J] .中华医学杂志, 2021, 101(1): 11-51. https://doi.org/10.3760/cma.j.cn112137-20201008-02778
|
[2]
|
Vonk, N.A., Chin, K.M., Haddad, F., et al. (2018) Pathophysiology of the Right Ventricle and of the Pulmonary Circulation in Pulmonary Hypertension: An Update. European Respiratory Journal, 53, Article ID: 1801900.
https://doi.org/10.1183/13993003.01900-2018
|
[3]
|
Humbert, M., Guignabert, C., Bonnet, S., et al. (2018) Pathol-ogy and Pathobiology of Pulmonary Hypertension: State of the Art and Research Perspectives. European Respiratory Journal, 53, Article ID: 1801887.
https://doi.org/10.1183/13993003.01887-2018
|
[4]
|
Huertas, A. and Guignabert, C. (2018) Pulmonary Vascular Endothelium: Orchestra Conductor in Respiratory Diseases Highlights from Basic Research to Therapy. European Res-piratory Journal, 51, Article ID: 1700745.
https://doi.org/10.1183/13993003.00745-2017
|
[5]
|
Claire, M. and Maurice, B. (2012) Inhaled Iloprost for the Control of Acute Pulmonary Hypertension in Children: A Systematic Review. Pediatric Critical Care Medicine, 13, 472-480. https://doi.org/10.1097/PCC.0b013e31822f192b
|
[6]
|
Stacey, E.B. and Rebecca, H.H. (2005) Inhaled Il-oprost in Pulmonary Arterial Hypertension. Annals of Pharmacotherapy, 39, 1265-1274. https://doi.org/10.1345/aph.1E575
|
[7]
|
Wilkens, H., Bauer, M., Forestier, N., et al. (2003) Influence of Inhaled Il-oprost on Transpulmonary Gradient of Big Endothelin in Patients with Pulmonary Hypertension. Circulation, 107, 1509-1513.
https://doi.org/10.1161/01.CIR.0000056104.49686.4B
|
[8]
|
Giaid, A. and Saleh, D. (1995) Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension. The New England Journal of Medicine, 333, 214-221.
https://doi.org/10.1056/NEJM199507273330403
|
[9]
|
Beghetti, M., Reber, G., de Moerloose, P., et al. (2002) Aerosolized Iloprost Induces a Mild but Sustained Inhibition of Platelet Aggregation. European Respiratory Journal, 19, 518-524. https://doi.org/10.1183/09031936.02.00094302
|
[10]
|
Nathan, D. and David, K. (2011) Bosentan for the Treatment of Adult Pulmonary Hypertension. Future Cardiology, 7, 19-37. https://doi.org/10.2217/fca.10.114
|
[11]
|
Roux, S., Breu, V., Ertel, S.I., et al. (1999) Endothelin Antagonism with Bosentan: A Review of Potential Applications. Journal of Molecular Medicine, 77, 364-376. https://doi.org/10.1007/s001090050363
|
[12]
|
Kim, H., Yung, G.L., Marsh, J.J., et al. (2000) Endothelin Mediates Pulmonary Vascular Remodelling in a Canine Model of Chronic Embolic Pulmonary Hypertension. European Respira-tory Journal, 15, 640.
https://doi.org/10.1034/j.1399-3003.2000.15d04.x
|
[13]
|
Chen, S.J., Chen, Y.F., Meng, Q.C., et al. (1995) Endo-thelinreceptor Antagonist Bosentan Prevents and Reverses Hypoxic Pulmonary Hypertension in Rats. Journal of Applied Physiology, 79, 2122-2131.
https://doi.org/10.1152/jappl.1995.79.6.2122
|
[14]
|
Alexander, M.K., Rothman, N.D.A., et al. (2015) Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure and Induces Histological Changes in an Acute Porcine Model of Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 8, e002569. https://doi.org/10.1161/CIRCINTERVENTIONS.115.002569
|
[15]
|
Jiang, X.M., Zhang, J., Zhou, L., et al. (2020) Sympathetic Innervation of Canine Pulmonary Artery and Morphometric and Functional Analysis in Dehydromono-crotaline-Induced Models after Pulmonary Artery Denervation. Interactive CardioVascular and Thoracic Surgery, 31, 708-717. https://doi.org/10.1093/icvts/ivaa166
|
[16]
|
Ciarka, A., Doan, V., Velez-Roa, S., et al. (2010) Prognostic Significance of Sympathetic Nervous System Activation Inpulmonary Arterial Hypertension. American Journal of Res-piratory and Critical Care Medicine, 181, 1269-1275.
https://doi.org/10.1164/rccm.200912-1856OC
|
[17]
|
Salvi, S.S. (1999) Alpha1-Adrenergic Hypothesis for Pulmo-nary Hypertension. Chest, 115, 1708-1719.
https://doi.org/10.1378/chest.115.6.1708
|
[18]
|
Zhao, Q., Deng, H., Jiang, X., et al. (2015) Effects of Intrinsic and Extrinsic Cardiac Nerves on Atrial Arrhythmia in Experimental Pulmonary Artery Hypertension. Hypertension, 66, 1042-1049.
https://doi.org/10.1161/HYPERTENSIONAHA.115.05846
|
[19]
|
Rubin, L.J., Badesch, D.B., Barst, R.J., et al. (2002) Bosentan Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine, 346, 896-903. https://doi.org/10.1056/NEJMoa012212
|
[20]
|
Galiè, N., Hinderliter, A.L., Torbicki, A., et al. (2003) Effects of the Oral Endothelin-Receptor Antagonist Bosentan on Echocardiographic and Doppler Measures in Patients with Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 41, 1380-1386. https://doi.org/10.1016/S0735-1097(03)00121-9
|
[21]
|
McLaughlin, V., Channick, R.N., Ghofrani, H.A., et al. (2015) Bosentan Added to Sildenafil Therapy in Patients with Pulmonary Arterial Hypertension. European Respiratory Journal, 46, 405-413.
https://doi.org/10.1183/13993003.02044-2014
|
[22]
|
Galiè, N., Rubin, L., Hoeper, M., et al. (2008) Treatment of Patients with Mildly Symptomatic Pulmonary Arterial Hypertension with Bosentan (EARLY Study): A Double-Blind, Randomised Controlled Trial. The Lancet, 371, 2093-2100.
https://doi.org/10.1016/S0140-6736(08)60919-8
|
[23]
|
Badesch, D.B., Bodin, F., Channick, R.N., et al. (2002) Complete Results of the First Randomized, Placebo-Controlled Study of Bosentan, a Dual Endothelin Receptor Antago-nist, in Pulmonary Arterial Hypertension. Current Therapeutic Research—Clinical and Experimental, 63, 227-246. https://doi.org/10.1016/S0011-393X(02)80029-7
|
[24]
|
Kiowski, W., Sütsch, G., Hunziker, P., et al. (1995) Evi-dence for Endothelin-1-Mediated Vasoconstriction in Severe Chronic Heart Failure. The Lancet, 346, 732-736. https://doi.org/10.1016/S0140-6736(95)91504-4
|
[25]
|
Nashat, H., Kempny, A., Harries, C., et al. (2020) A Sin-gle-Centre, Placebo-Controlled, Double-Blind Randomised Cross-Over Study of Nebulised Iloprost in Patients with Ei-senmenger Syndrome: A Pilot Study. International Journal of Cardiology, 299, 131-135. https://doi.org/10.1016/j.ijcard.2019.07.004
|
[26]
|
Xu, Z., Zhu, L., Liu, X., et al. (2014) Iloprost for Children with Pulmonary Hypertension after Surgery to Correct Congenital Heart Disease. European Heart Journal, 35, 78.
|
[27]
|
Rex, S., Schaelte, G., Metzelder, S., et al. (2008) Inhaled Iloprost to Control Pulmonary Artery Hypertension in Patients Un-dergoing Mitral Valve Surgery: A Prospective, Randomized-Controlled Trial. Acta Anaesthesiologica Scandinavica, 52, 65-72. https://doi.org/10.1111/j.1399-6576.2007.01476.x
|
[28]
|
McLaughlin, V.V., Oudiz, R.J., Frost, A., et al. (2006) Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension. Ameri-can Journal of Respiratory and Critical Care Medicine, 174, 1257- 1263. https://doi.org/10.1164/rccm.200603-358OC
|
[29]
|
Olschewski, H., Simonneau, G., Galiè, N., et al. (2002) Inhaled Iloprost for Severe Pulmonary Hypertension. The New England Journal of Medicine, 347, 322-329. https://doi.org/10.1056/NEJMoa020204
|
[30]
|
Zhang, H., Zhang, J., Chen, M., et al. (2019) Pulmonary Artery De-nervation Significantly Increases 6-Min Walk Distance for Patients with Combined Pre- and Post-Capillary Pulmonary Hypertension Associated with Left Heart Failure: The PADN-5 Study. JACC: Cardiovascular Interventions, 12, 274-284. https://doi.org/10.1016/j.jcin.2018.09.021
|
[31]
|
Romanov, A., Cherniavskiy, A., Novikova, N., et al. (2020) Pulmonary Artery Denervation for Patients with Residual Pulmonary Hypertension after Pulmonary Endarterec-tomy. Journal of the American College of Cardiology, 76, 916- 926. https://doi.org/10.1016/j.jacc.2020.06.064
|
[32]
|
Karaskov, A.M., Bogachev-Prokophiev, A.V., Demidov, D.P., et al. (2017) Perspective Directions in Management of Severe Group Two Pulmonary Hypertension. Kardiologiia, 57, 23-28. https://doi.org/10.18087/cardio.2017.11.10050
|
[33]
|
Trofimov, N.A., Medvedev, A.P., Nikolsky, A.V., et al. (2019) Denervation of Pulmonary Arteries in Patients with Mitral Valve Defects Complicated by Atrial Fibrillation and Pulmo-nary Hypertension. Sovremennye Tehnologii v Medicine, 11, 95-103. https://doi.org/10.17691/stm2019.11.4.11
|
[34]
|
Carla, F. andrew, H.C., Stephen, J.W., et al. (2019) Eisenmenger Syndrome and Other Types of Pulmonary Arterial Hypertension Related to Adult Congenital Heart Disease. Expert Re-view of Cardiovascular Therapy, 17, 449-459.
https://doi.org/10.1080/14779072.2019.1623024
|
[35]
|
Lapenna, E., De Bonis, M., Giambuzzi, I., et al. (2020) Long-Term Outcomes of Stand-Alone Maze IV for Persistent/ Long-Standing Persistent Atrial Fibrillation. The Annals of Thoracic Surgery, 109, 124-131.
https://doi.org/10.1016/j.athoracsur.2019.05.061
|
[36]
|
Camilla, S.E., Kenneth, B.P., Lars, P.R., et al. (2018) The Long-Term Efficacy of Concomitant Maze IV Surgery in Patients with Atrial Fibrillation. IJC Heart & Vasculature, 19, 20-26. https://doi.org/10.1016/j.ijcha.2018.03.009
|